Pfizer: The third dose for children under 5 years is 80% effective against omicron
According to the results of the clinical trial, the three-dose vaccine Pfizer and BioNTech for children from six months to 5 years was 80% effective in preventing disease during the omicron wave.
A third dose of the vaccine elicited a strong immune response and was well tolerated by the children's body.
Pfizer and the Food and Drug Administration had initially sought to speed up authorization of the first two doses in February so that parents could start vaccinating their children while clinical trial results from the third vaccine were still pending.
Children under the age of 5 are the only group in the US not yet eligible for vaccination. Parents have been waiting for months for the FDA to authorize injections.
According to U.S. health authorities, during the massive wave of omicron infection during the winter, children younger than 5 years old were hospitalized with Covid in very high numbers.